Sponsored By

KitoZyme, University of Liège Introduce SynolyneKitoZyme, University of Liège Introduce Synolyne

April 24, 2013

1 Min Read
KitoZyme, University of Liège Introduce Synolyne

HERSTAL, BelgiumKitoZyme and the University of Liège have partnered to create Synolyne, a new project dedicated to arthrosis treatment for joint health and cartilage repair.

Synolyne will focus on the research, development and marketing of a patented medical device designed to treat arthrosis by promoting cartilage repair. Synolyne will also use an arthrotic joint supplementation that contains micropearls of KiOmedine-CsU ®, KitoZyme's pure chitosan of non-animal origin .

In January, KitoZyme announced François Blondel as its new CEO. Blondel, 49, was appointed to the company's board of directors on Nov. 30, 2012.

Subscribe and receive the latest insights on the healthy food and beverage industry.
Join 47,000+ members. Yes, it's completely free.

You May Also Like